RXi Pharmaceuticals Corporation (NASDAQ:RXII) shares saw unusually-strong trading volume on Wednesday . Approximately 1,438,371 shares traded hands during trading, an increase of 399% from the previous session’s volume of 288,155 shares.The stock last traded at $0.55 and had previously closed at $0.49.

The company’s market cap is $12.32 million. The company’s 50-day moving average is $0.52 and its 200 day moving average is $0.60.

RXi Pharmaceuticals Corporation (NASDAQ:RXII) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.11) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.11). During the same period in the prior year, the firm posted ($0.34) earnings per share. Analysts forecast that RXi Pharmaceuticals Corporation will post ($1.77) EPS for the current year.

In other news, insider Alexey Eliseev sold 176,800 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $0.54, for a total transaction of $95,472.00. Following the sale, the insider now owns 1,100,931 shares in the company, valued at approximately $594,502.74. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 5.71% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/13/rxi-pharmaceuticals-corporation-rxii-sees-large-volume-increase.html.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Receive News & Stock Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related stocks with our FREE daily email newsletter.